RBD-1016

N/A

Report date: 2025/10/31 18:01:23
NME

Base Information

Drug NameRBD-1016
Drug Alias NameRBD-1016SR-016
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceHepatitis B virus protein X inhibitorsAsialoglycoprotein receptor modulators
TargetsHepatitis B virus protein XAsialoglycoprotein receptor
Therapy Area/IndicationsHepatitis D, ChronicHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenAustraliaHong Kong +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Ribo Life Science Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesRibo (Suzhou) Pharmaceutical Co LtdRibocure Pharmaceuticals ABSuzhou Ribo Life Science Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis D, ChronicHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A